Company Overview
Company Type: Private Company
Website: www.biolytical.com
Number of Employees: 50
Year Founded: 2002
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
bioLytical Laboratories Inc. develops and manufactures diagnostic products. It provides INSTI, a HIV-1/HIV-2 rapid antibody test used for the detection of antibodies to human immunodeficiency virus type 1 in human whole blood, serum, or plasma; and INSTI COVID-19 Antibody Test, a one-minute antibody test for COVID-19. The company sells its products through distributors in Canada and India. bioLytical Laboratories Inc. was founded in 2002 and is based in Richmond, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 17.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 50
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Mackie, Robert 
Chairman & CEO
Wong, Lawrence 
Chief Financial Officer
Croukamp, Hans 
COO & Director
Zaharik, Michelle 
Chief Scientific Officer
Fleming, Brent 
Chief People Officer
Rathbone, Sean 
Senior Vice President of Operations
Shackleton, Christopher R.
Executive Director

Key Board Members
Name
Title
Mackie, Robert 
Chairman & CEO
Croukamp, Hans 
COO & Director
Shackleton, Christopher R.
Executive Director
Bligh, Philip
Director
Gelfand, Robert 
Director
Harrigan, Brian
Member of Scientific Advisory Board
Harrigan, Richard
Member of Scientific Advisory Board
Major, Carol
Member of Scientific Advisory Board
Tyndall, Mark 
Member of Scientific Advisory Board
Washington, Kyle R.
Director
Weinstein, Michael 
Director
Westgard, Charles 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
406 - 13251 Delf Place | Richmond, BC | V6V 2A2 | Canada
Phone: 604-204-6784   Fax: 604-244-8399


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-05-2016
Nov-21-2016
Merger/Acquisition
Seller
Network Life Sciences Inc. (nka:e-Play Digital Inc.,)
E-Play Digital Inc. (CNSX:EPY)
Web Watcher Systems Ltd.,Resolute Oncology Limited,bioLytical Laboratories Inc.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-27-2023
Product-Related Announcements
bioLytical Laboratories Inc. Receives Health Canada Authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test
Oct-18-2022
Product-Related Announcements
bioLytical Laboratories Inc. Receives WHO PQ for Its iStatis COVID-19 Antigen Home Test
Apr-02-2022
Product-Related Announcements
Biolytical Laboratories Inc. Receives Health Canada Authorization for the Istatis Covid-19 Antigen Home Test
Mar-21-2022
Product-Related Announcements
BioLytical Laboratories Inc. Receives CE Mark for iStatis COVID-19 Antigen Home Test
Mar-07-2022
Product-Related Announcements
Biolytical Laboratories Inc. Receives Health Canada Authorization for Its iStatis Covid-19 Antigen Test

Competitors
Alere Inc., Atomo Diagnostics Limited (ASX:AT1), OraSure Technologies, Inc. (NasdaqGS:OSUR), Trinity Biotech plc (NasdaqGS:TRIB)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 12:36 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
51
GlobalData

Sep 15, 2023 05:28 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc - Medical Devices Product Pipeline Summary
Reports
46
GlobalData

Jun 16, 2023 12:59 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
51
GlobalData

Mar 17, 2023 02:58 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
51
GlobalData

Mar 10, 2023 02:10 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc - Medical Devices Product Pipeline Summary
Reports
46
GlobalData

Dec 14, 2022 06:33 PM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
52
GlobalData

Dec 09, 2022 09:34 PM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc - Medical Devices Product Pipeline Summary
Reports
46
GlobalData

Sep 21, 2022 03:44 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
51
GlobalData

Sep 15, 2022 06:32 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc - Medical Devices Product Pipeline Summary
Reports
47
GlobalData

Jun 15, 2022 01:05 AM
bioLytical Laboratories Inc.
bioLytical Laboratories Inc
Reports
52


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
INSTI HIV Test

Key Board Members Details
Name
Title
Phone
Fax
Email
Mackie, Robert 
Chairman & CEO
604-204-6784
604-244-8399

Croukamp, Hans 
COO & Director
604-204-6784
604-244-8399

Shackleton, Christopher R.
Executive Director
604-204-6784
604-244-8399

Bligh, Philip
Director
604-204-6784
604-244-8399
-
Gelfand, Robert 
Director
604-204-6784
604-244-8399

Harrigan, Brian
Member of Scientific Advisory Board
604-204-6784
604-244-8399
-
Harrigan, Richard
Member of Scientific Advisory Board
604-204-6784
604-244-8399
-
Major, Carol
Member of Scientific Advisory Board
604-204-6784
604-244-8399
-
Tyndall, Mark 
Member of Scientific Advisory Board
604-204-6784
604-244-8399

Washington, Kyle R.
Director
604-204-6784
604-244-8399

Weinstein, Michael 
Director
604-204-6784
604-244-8399

Westgard, Charles 
Director
604-204-6784
604-244-8399

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mackie, Robert 
Chairman & CEO
604-204-6784
604-244-8399

Wong, Lawrence 
Chief Financial Officer
604-204-6784
604-244-8399

Croukamp, Hans 
COO & Director
604-204-6784
604-244-8399

Zaharik, Michelle 
Chief Scientific Officer
604-204-6784
604-244-8399

Fleming, Brent 
Chief People Officer
604-204-6784
604-244-8399
-
Rathbone, Sean 
Senior Vice President of Operations
604-204-6784
604-244-8399

Shackleton, Christopher R.
Executive Director
604-204-6784
604-244-8399

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
